{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:48:42Z","timestamp":1791676122283,"version":"4.3.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07145-3","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:23:52Z","timestamp":1783020232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014\u20132024)"],"prefix":"10.1007","volume":"105","author":[{"given":"Utsav","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Tuz","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pujan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagehan","family":"Pakasticali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishakha","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rory","family":"Shallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoer","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongseok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-1961","authenticated-orcid":false,"given":"Onyee","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"12","key":"7145_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136\u201352","journal-title":"N Engl J Med"},{"key":"7145_CR2","unstructured":"National Cancer Institute Cancer Stat Facts: Acute Myeloid Leukemia (AML). SEER. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html. Accessed 2025 Nov 24"},{"issue":"16_suppl","key":"7145_CR3","doi-asserted-by":"publisher","first-page":"6543","DOI":"10.1200\/JCO.2024.42.16_suppl.6543","volume":"42","author":"P Dhakal","year":"2024","unstructured":"Dhakal P, Loeffler BT, Ravindra A, Acharya L, Pyakuryal A, Bhatt VR (2024) Improved overall survival in acute myeloid leukemia over the last 15 years. J Clin Oncol 42(16_suppl):6543\u20136543","journal-title":"J Clin Oncol"},{"key":"7145_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387","journal-title":"Blood Rev"},{"issue":"17","key":"7145_CR5","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1182\/bloodadvances.2024013102","volume":"8","author":"H Liu","year":"2024","unstructured":"Liu H, Stanworth SJ, McPhail S, Bishton M, Rous B, Bacon A et al (2024) Impact of patient demographics on treatment outcomes in AML: a population-based registry in England, 2013\u20132020. Blood Adv 8(17):4593\u2013605","journal-title":"Blood Adv"},{"issue":"5","key":"7145_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300637","volume":"19","author":"HJ Han","year":"2024","unstructured":"Han HJ, Choi K, Suh HS (2024) Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: a real-world, population-based longitudinal cohort study. PLoS One 19(5):e0300637","journal-title":"PLoS One"},{"issue":"1","key":"7145_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jgo.2015.10.182","volume":"7","author":"B Tawfik","year":"2016","unstructured":"Tawfik B, Pardee TS, Isom S, Sliesoraitis S, Winter A, Lawrence J et al (2016) Comorbidity, age, and mortality among adults treated intensively for acute myeloid leukemia (AML). J Geriatr Oncol 7(1):24\u201331","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"7145_CR8","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/10428194.2023.2165394","volume":"64","author":"P Dhakal","year":"2023","unstructured":"Dhakal P, Lyden E, Joshi U, Pyakuryal A, Loh KP, Klepin H et al (2023) Comorbidity burden and outcomes of older adults with acute promyelocytic leukemia: a National Cancer Database analysis of 2221 patients. Leuk Lymphoma 64(3):691\u20137","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"7145_CR9","doi-asserted-by":"publisher","first-page":"e241112","DOI":"10.1001\/jamanetworkopen.2024.1112","volume":"7","author":"LH Nielsen","year":"2024","unstructured":"Nielsen LH, Kristensen DT, Jakobsen LH, B\u00f8gsted M, Gregersen H, Madsen J et al (2024) Socioeconomic status and overall survival among patients with hematological malignant neoplasms. JAMA Netw Open 7(3):e241112","journal-title":"JAMA Netw Open"},{"issue":"20","key":"7145_CR10","doi-asserted-by":"publisher","first-page":"5297","DOI":"10.1182\/bloodadvances.2024013685","volume":"8","author":"FW Hoff","year":"2024","unstructured":"Hoff FW, Blum WG, Huang Y, Welkie RL, Swords RT, Traer E et al (2024) Beat-AML 2024 ELN\u2013refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv 8(20):5297\u2013305","journal-title":"Blood Adv"},{"issue":"12","key":"7145_CR11","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u201377","journal-title":"Blood"},{"issue":"2","key":"7145_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/COC.0b013e31828d7536","volume":"38","author":"MI Patel","year":"2015","unstructured":"Patel MI, Ma Y, Mitchell BS, Rhoads KF (2015) Age and genetics. Am J Clin Oncol 38(2):159\u201364","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"7145_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/2159-8290.CD-20-1579","volume":"11","author":"B Bhatnagar","year":"2021","unstructured":"Bhatnagar B, Kohlschmidt J, Mr\u00f3zek K, Zhao Q, Fisher JL, Nicolet D et al (2021) Poor survival and differential impact of genetic features of Black patients with acute myeloid leukemia. Cancer Discov 11(3):626\u201337","journal-title":"Cancer Discov"},{"issue":"19","key":"7145_CR14","doi-asserted-by":"publisher","first-page":"5570","DOI":"10.1182\/bloodadvances.2022007544","volume":"6","author":"KT Larkin","year":"2022","unstructured":"Larkin KT, Nicolet D, Kelly BJ, Mr\u00f3zek K, LaHaye S, Miller KE et al (2022) High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML. Blood Adv 6(19):5570\u201381","journal-title":"Blood Adv"},{"issue":"24","key":"7145_CR15","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1182\/bloodadvances.2017007013","volume":"1","author":"K Darbinyan","year":"2017","unstructured":"Darbinyan K, Shastri A, Budhathoki A, Helbig D, Snyder R, Pradhan K et al (2017) Hispanic ethnicity is associated with younger age at presentation but worse survival in acute myeloid leukemia. Blood Adv 1(24):2120\u20133","journal-title":"Blood Adv"},{"issue":"4","key":"7145_CR16","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/jha2.589","volume":"3","author":"T Bradley","year":"2022","unstructured":"Bradley T, Kwon D, Monge J, Sekeres M, Chandhok N, Thomassen A et al (2022) Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia. EJHaem 3(4):1231\u201340","journal-title":"EJHaem"},{"issue":"16_suppl","key":"7145_CR17","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1200\/JCO.2023.41.16_suppl.7032","volume":"41","author":"N Premnath","year":"2023","unstructured":"Premnath N, Khan A, Pandey M, Pandey U, Hoff FW, Chung S et al (2023) Shattering myths regarding Hispanic ethnicity and survival in acute myeloid leukemia: insights from the National Cancer Database. J Clin Oncol 41(16_suppl):7032\u20137032","journal-title":"J Clin Oncol"},{"key":"7145_CR18","unstructured":"Moffitt Cancer Center (2026) About Our Catchment Area. Available from: https:\/\/www.moffitt.org\/research-science\/community-outreach-and-engagement\/catchment-area\/. Accessed May 28"},{"issue":"Supplement 1","key":"7145_CR19","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1182\/blood-2024-212140","volume":"144","author":"JD Gonzalez-Lugo","year":"2024","unstructured":"Gonzalez-Lugo JD, Madanat YF, Zapata N, Nicolet D, Klein V, Foucar C et al (2024) Molecular features of acute myeloid leukemia in Hispanics: an analysis from the Marrow Consortium. Blood 144(Supplement 1):3801\u20133801","journal-title":"Blood"},{"issue":"6_Supplement_1","key":"7145_CR20","doi-asserted-by":"publisher","first-page":"C061","DOI":"10.1158\/1538-7755.DISP18-C061","volume":"29","author":"A Gomez-Arteaga","year":"2020","unstructured":"Gomez-Arteaga A, Mencia-Trinchant N, Tovar AM, Carrillo IO, Laguna AG, Fuller ER et al (2020) Abstract C061: molecular landscape of acute myeloid leukemia in Mexico. Cancer Epidemiol Biomarkers Prev 29(6_Supplement_1):C061\u2013C061","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"7145_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102549","volume":"71","author":"MS Linet","year":"2024","unstructured":"Linet MS, Curtis RE, Schonfeld SJ, Vo JB, Morton LM, Dores GM (2024) Survival of adult AML patients treated with chemotherapy in the U.S. population by age, race and ethnicity, sex, calendar-year period, and AML subgroup, 2001\u20132019. EClinicalMedicine 71:102549","journal-title":"EClinicalMedicine"},{"issue":"1","key":"7145_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01332-7","volume":"15","author":"DT Kristensen","year":"2025","unstructured":"Kristensen DT, Br\u00f8ndum RF, Knudsen M, Severinsen MT, Grubach L, Andersen MK et al (2025) Outcomes and prognostic impact of trisomy 8 in acute myeloid leukemia patients treated with intensive chemotherapy. Blood Cancer J 15(1):146","journal-title":"Blood Cancer J"},{"issue":"5","key":"7145_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2020008812","volume":"138","author":"ML Sorror","year":"2021","unstructured":"Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA et al (2021) Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood 138(5):387\u2013400","journal-title":"Blood"},{"issue":"12","key":"7145_CR24","doi-asserted-by":"publisher","first-page":"13687","DOI":"10.1002\/cam4","volume":"12","author":"K Kirtane","year":"2023","unstructured":"Kirtane K, Zhao Y, Amorrortu RP, Fuzzell LN, Vadaparampil ST, Rollison DE (2023) Demographic disparities in receipt of care at a comprehensive cancer center. Cancer Med 12(12):13687\u201313700. https:\/\/doi.org\/10.1002\/cam45992 PubMed PMID: 37114585","journal-title":"Cancer Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07145-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07145-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07145-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:05:20Z","timestamp":1791673520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07145-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7145"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07145-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Sallman- Consultancy: AbbVie, Agios, Debiopharm, Janssen, Johnson & Johnson, Molecular Partners, Novartis. Advisory Board: AbbVie, Agios, Astellas, AvenCell, Bristol-Myers Squibb, BlueBird Bio, Dark Blue Therapeutics, Geron, Novartis, Shattuck Labs, Servier, Syndax, Syros, Taiho Oncology. Research Funding: Aprea, Jaz. Andrew Kuykendall- Consultancy\/Honoraria: Abbvie, Blueprint Medicines, Celgene\/BMS, CTI Biopharma, DISC Medicine, Geron, GSK, Incyte, Karyopharm, MorphoSys, Novartis, PharmaEssentia, Protagonist, Silence Therapeutics. Research Funding: AJAX, Blueprint Medicines, BMS, Geron, GSK, Janssen, Kartos, MorphoSys, Novartis, Protagonist. Rami Komrokji- Abbvie: consulting. BMS: Research Grant, Advisory board. DSI: Advisory board and speaker bureau. Geron: Consultancy. GSK: Advisory board. Takeda- steering committee, consultancy. Pharma Essentia: Speaker Bureau, Advisory board. Rigel: Speaker Bureau, Advisory board. Novartis: Advisory board. Servier: Speaker Bureau, Advisory board. Sobi: Speaker Bureau, Advisory board. Stem line: Advisory board. Sumitomo Pharma: Advisory board. Jeffrey Lancet- Stemline Therapeutics \u2013 Consultant. GLG Consulting \u2013 Consultant. Biomea Fusion, Inc. \u2013 Research Funding (to institution). Jasper Therapeutics, Inc. \u2013 Research Funding (to institution). Onyee Chan- has served in a consulting or advisory role for Bristol Myers Squibb, Novartis, Servier, Syndax, and Takeda; has received honoraria from AbbVie, Aptitude Health, and OncLive; has received research funding from AbbVie, Cullinan Florentine, Daiichi-Sankyo, Jazz Pharmaceuticals, Kumquat, and Remix Therapeutics.\u00a0Rest of the authors do not have any competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"427"}}